exagen.com (XGN) - Long-Term Debt to Capital Ratio

Corporate emblem and logo of Exagen Inc (XGN)

Exagen Inc. (XGN) is integrating AI into predictive pathology diagnostics via the Avise system, advancing digital healthcare. This chart, featuring the 2.08 metric, links scientific progress to the premium pricing of unique tests for complex diagnoses. Operational activities rely on the US legal framework, which eliminates geopolitical risks and guarantees stable demand for medical services.

Exagen (XGN): Long-Term Debt to Equity from 07/04/2022 to 10/31/2026

Analytical breakdowns for Exagen Inc.

- market price and analyst price targets:
Market Price Exagen Diagnostics|XGN - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Exagen|XGN - Enterprise Value
- issuer book value statistics:
Book Value per Share Exagen Inc.|XGN - Company Book Value|Capitalization to Book Value Ratio exagen.com|XGN - Company Total Assets
- debt and solvency information:
Total Debt to Capital Exagen Inc.|XGN - Long-Term Debt to Equity|Short-Term Debt to Equity Exagen Diagnostics|XGN - Company Total Debt|Debts to Book Value Exagen|XGN - Company Long-Term Debt|Short-Term Debt Volume Exagen Inc.|Interim Coverage Ratio exagen.com
- net income and valuation ratios data:
XGN - Company Net Income
General company analysis:XGN (exagen.com)
Core merchandise of Exagen Diagnostics

This indicator determines the degree of financial leverage by comparing liabilities with maturities exceeding one year to the amount of equity to assess debt sustainability. By analyzing the proportion of long-term loans to equity, an investor can evaluate the ability of Exagen Inc. (XGN) to finance the digital transformation of diagnostics and the environmental modernization of laboratories without risking insolvency.

Analysis of competing companies

Long-Term Liabilities to Capital Agilent Technologies, Inc. A|Long-Term Debt to Capital DGX|Illumina Platform - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital EXAS (Exact Sciences)|Long-Term Debt to Capital revvity.com RVTY|BIO - Long-Term Debt to Equity|NNNN (Anbio Biotechnology Ltd) - Long-Term Debt to Capital Ratio|SHC: Long-Term Debt to Capital|QuidelOrtho Inc. (QDEL) - Long-Term Debt to Capital|Long-Term Debt to Equity OPKO Health, Inc.|Long-Term Debt to Equity CDNA|Long-Term Debt to Equity Ratio MRVI (Maravai LifeSciences Holdings, Inc.)|FLGT - Long-Term Liabilities to Capital|Long-Term Debt to Equity Fluidigm LAB|Ratio of Long-Term Indebtedness to Capital Cytek Corp (CTKB)|OraSure Technologies - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital mdxhealth.com MDXH|Lucid Diagnostics (LUCD) - Long-Term Debt to Equity|PRE - Ratio of Long-Term Indebtedness to Capital|IMDX (Insight Molecular Diagnostics, Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Trinity Biotech Corp TRIB|Long-Term Debt to Equity Ratio PRPH (ProPhase Labs, Inc.)|ainos.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital CODX (Co-Diagnostics)|Long-Term Debt to Capital Heart Test Laboratories, Inc. HSCS|Biomerica, Inc - Long-Term Debt to Capital|Long-Term Indebtedness to Equity Cardio Diagnostics (CDIO)|VRAX: Long-Term Debt to Capital|Long-Term Liabilities to Capital bluejaydx.com (BJDX)|Long-Term Debt to Equity Aspira Women's Health Inc.|Long-Term Debt to Capital Ratio AXDX (Accelerate Diagnostics Inc.)|Long-Term Debt to Equity Ratio CNTG (CENTOGENE, N.V.)|ENZ (enzo.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital FRES (Fresh2 Group)|Ratio of Long-Term Indebtedness to Capital Genetic Technologies Ltd (GENE)|ME - Long-Term Debt to Equity|PMD (Psychemedics Corp.) - Long-Term Debt to Capital Ratio